Quick Answer
Replimune Group, Inc. reported R&D Expense of $189.45 million for fiscal year 2025.
Replimune Group, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $189.45M | +8.3% |
| 2024 | $174.96M | +38.3% |
| 2023 | $126.53M | +59.1% |
| 2022 | $79.55M | +40.2% |
| 2021 | $56.75M | +46.4% |
| 2020 | $38.76M | +74.8% |
| 2019 | $22.17M | +64.1% |
| 2018 | $13.52M | +94.9% |
| 2017 | $6.94M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $53.14M | +10.7% | -8.2% |
| September 30, 2025 | $57.88M | +33.2% | +0.1% |
| June 30, 2025 | $57.84M | +34.6% | +20.5% |
| December 31, 2024 | $48.00M | +12.0% | +10.5% |
| September 30, 2024 | $43.45M | -11.5% | +1.1% |
| June 30, 2024 | $42.97M | +6.3% | +0.3% |
| December 31, 2023 | $42.85M | +41.6% | -12.7% |
| September 30, 2023 | $49.10M | +70.3% | +21.4% |
- Replimune Group, Inc. showed an increase of +8.3% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Replimune Group, Inc.’s r&d expense has grown by 2631.4% (from $6.94 million to $189.45 million).
- The most recent figure is from Replimune Group, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: